Table 1.
Exosomal lncRNAs involved in drug resistance
| lncRNA | Cancer type | Cell line | Drug | Mechanism | Ref. |
|---|---|---|---|---|---|
| UCA 1 | BC (Estrogen receptor positive) | MCF-7, LCC2 | Tamoxifen (HT) | Not stated | Xu et al.[99] |
| SNHG14 | BC [Human epidermal growth factor receptor 2 (HER2) positive] | SKBR-2, BT474 | Trastuzumab (TT) | Targets Bcl-2 and Bax apoptosis pathway | Dong et al.[90] |
| UCA1 | CRC | Caco2 | Cetuximab (TT) | Not stated | Yang et al.[91] |
| PART1 | Esophageal squamous cell carcinoma | TE1, KYSE-450 | Gefitinib (TT) | Competitive binding to miR-129 increasing Bcl-2 expression. | Kang et al.[92] |
| SBF2-AS1 | GBM | U87,LN229, A172, T98, U251 | Temozolomide (CT) | Acts as a ceRNA for miR-151a-3p, desinhibits XRCC4 target, reparing DSB. | Zhang et al.[87] |
| Linc-VLDLR | HCC | MzChA-1, Huh-7, HepG2, PLC-PRF-5, Hep3B | Several drugs: sorafenib (TT), camptothecin (CT), doxorubicin(CT) | ABCG2 | Takahashi et al.[88] |
| Linc-ROR | HCC | HepG2, PLC-PRF5 | Several drugs: sorafenib (TT), doxorubicin (CT) | TGFβ enriches linc-ROR in extracelular vesicles. | Takahashi et al.[89] |
| H19 | NSCLC | HCC827, HCC4006 | Gefitinib (TT) | Not stated | Lei et al.[93] |
| RP11-838N2.4 | NSCLC | HCC827, HCC4006 | Erlotinib (TT) | This lncRNA is negatively regulated by FOXO1 | Zhang et al.[94] |
| lncARSR | RCC | ACSu3rd, 7Su3rd. | Sunitinib (TT) | Facilitate AXL and c-MET expression by competitive binding to miR-34/miR-449. | Qu et al.[25] |
CT: Chemotherapy; TT: targeted therapy; HT: hormone therapy; BC: breast cancer; CRC: colorectal cancer; GBM: glioblastoma multiforme; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; ABCG2: ATP-binding cassette, sub-family G member 2; TGFβ: Transforming growth factor β; DSB: double-strand breaks